The Patent Is a Shield. The Real Question Is Whether Vivos Is Building a Sword.

Vivos Therapeutics announced on August 5th that the USPTO issued Patent No. 12,697,190 - a continuation of a 2024 patent covering its vibrational oral appliance technology for treating sleep apnea. The press release is careful to frame this as broadening and strengthening protection. Headlines call it expanding protection.

But patents don't create markets. They only keep other people from entering ones you've already built. And that's the thing about Vivos: it hasn't really built one yet.

The more useful question isn't whether competitors can now more easily design around Vivos' technology. It's whether Vivos itself can figure out how to reach the people who actually need it.

Vivos makes what it calls CARE - Complete Airway Repositioning and/or Expansion - oral appliances. The short version: a custom-fitted dental device that uses vibration and jaw repositioning to treat obstructive sleep apnea. Unlike CPAP machines, which force air into your throat while you sleep, Vivos aims to change the physical structure of the airway itself. The company claims about 80% of patients achieve significant symptom reduction or complete resolution, measured by standard AHI scores (Apnea-Hypopnea Index, which counts how many times breathing stops per hour of sleep).

What makes Vivos unusual in the crowded sleep-apnea landscape is its FDA status. In 2023, the FDA granted 510(k) clearance for CARE devices to treat severe obstructive sleep apnea in adults. In 2024, the DNA variant received clearance for moderate-to-severe OSA in children ages 6-17. No other oral appliance has received either of those clearances. That is not nothing.

The market for alternatives to CPAP has gotten more sympathetic. Philips Respironics recalled millions of CPAP, BiPAP, and ventilator devices starting in 2021 because foam inside the machines could break down and release inhaled particles or chemicals. The FDA directed the recall as a Class I event (the most serious category). As of mid-2026, a second round of FDA action hit replacement units for faulty programming. Over 5 million units affected across multiple recall waves. Patients who were already uncomfortable with CPAP's bulky mask-and-hose setup found themselves wondering whether the standard of care was safe.

Against that backdrop, a device that is FDA-cleared, non-surgical, and targets severe OSA sounds like exactly what the market needs. Vivos' press release cites up to 90 million Americans with sleep apnea, 80% of whom remain undiagnosed. The addressable market is enormous.

Enormous markets and narrow companies are not the same thing. The numbers tell a different story.

Full year 2025 revenue: $17.5 million, up 16% from 2024. Q1 2026 revenue: $5.1 million, up 70% year-over-year. Q1 2026 net loss: $7.8 million, up 100% from $3.9 million a year earlier. Cash at the end of Q1 2026: $2.1 million. Stockholders' equity: a deficit of $1.1 million.

The revenue growth is real and accelerating, but the company was barely above the water. It raised $6.8 million in post-year-end financings to stay alive. The 70% revenue jump in Q1 2026 came largely from the June 2025 acquisition of The Sleep Center of Nevada (SCN) - sleep testing services added roughly $2.0 million in the quarter, and treatment center revenue at two SCN locations contributed $0.9 million more. Without SCN, the underlying product revenue from legacy dentist customers actually declined, from $1.8 million to $1.4 million, as Vivos shifted toward lower-priced but higher-margin tooth positioners.

What's happening here is that Vivos has been quietly rewriting its entire business model while nobody was looking at the revenue line closely enough. The old model - enrolling and training dentists through the VIP (Vivos Integrated Provider) program, then recognizing enrollment revenue over time - was slow, expensive, and dependent on a distribution channel that doesn't naturally sell sleep apnea devices. In Q1 2026, there were zero new VIP dentist enrollments. The company stopped recruiting dentists.

The new model is to acquire or partner directly with sleep medical practices. Own the patient relationship. Control the diagnostic funnel. Revenue from appliance sales through SCN is now classified as service revenue rather than product sales. This is a fundamentally different animal: less a device manufacturer, more a vertically integrated sleep clinic operator.

This is where the patent story intersects with the business story in an unexpected way. Patents are normally discussed in the context of product protection - keeping competitors from copying your technology. But for a company that is trying to pivot from being a product seller to being a service operator, the patent does something else entirely. It's not just a moat around a product. It's collateral.

If Vivos is going to keep acquiring sleep centers, it needs financing. If investors are going to tolerate a negative equity position and a $7.8 million quarterly net loss, they need a reason to believe the future cash flows are defensible. A broadening patent portfolio is one of the few tangible assets a company this small can point to and say "this belongs to us, and no one else can do it."

The new '190 patent is a continuation of the '608 patent from July 2024. Continuation patents are a standard strategy - they take the same underlying invention but claim it in broader, design-independent terms. Where the '608 patent protected a specific structural embodiment, the '190 patent makes it harder for a competitor to sell a functionally equivalent device with a different physical configuration. Together they give what Vivos calls "broad, difficult-to-design-around protection" alongside "detailed, embodiment-specific protection".

That's true enough. But what a patent cannot do is enroll patients. What it cannot do is credential providers with insurance payors. What it cannot do is make a sleep center in Las Vegas reach capacity fast enough to turn a $7.8 million quarterly loss into positive cash flow - which is what management has publicly targeted for "the end of this year."

Let me put this in a frame that matters for someone thinking about the stock, which traded around $0.40-$0.42 as of July 31, 2026. Vivos has three things going for it: a cleared product that works for a serious medical condition, a pivot toward a business model that actually controls patient volume, and intellectual property that narrows the competitive field. It has three things going against it: a tiny revenue base that's still deeply unprofitable, a cash position that required emergency financing to avoid insolvency, and a strategy that depends on executing an unproven acquisition playbook while burning through cash faster than it earns it.

The patent doesn't change any of these numbers. It changes the odds that if Vivos survives its current financial fragility, the market it's building won't be immediately crowded by copycats. That's a valuable thing - but it's valuable in the future tense.

The question for an investor isn't whether Vivos has a defensible product. It's whether a company with $2.1 million in cash, a negative equity position, and a revenue base of $5 million per quarter can bridge the gap between now and the point where its acquisition model generates enough cash flow to matter. The patent is the shield. The real question is whether Vivos is building the sword - or just waiting for a market that may never arrive while it runs out of runway.

Here's the test worth watching: the next two earnings reports. If Q2 and Q3 2026 show the SCN model continuing to scale revenue while operating expenses stop growing faster than top line, the pivot has legs. If the losses keep widening past the year-end target management set, the patent is just a very elegant piece of paper protecting a business that didn't reach scale in time. One way or the other, the numbers will say something the press release can't.